Cyclacel Pharmaceuticals Inc. has released its financial results for the three months ended March 31, 2025. The company reported no revenue from clinical trial supply for the period, compared to $29,000 in the same period in 2024. Operating expenses increased to $5.036 million from $4.384 million in the previous year, driven by research and development expenses of $822,000 and general and administrative expenses of $4.214 million. The company incurred an operating loss of $5.036 million, compared to a loss of $4.355 million in the same period last year. Notably, Cyclacel recorded a gain of $4.947 million from the deconsolidation of a subsidiary. The company is focused on its clinical-stage biopharmaceutical operations, developing innovative cancer medicines targeting cell cycle, transcriptional regulation, epigenetics, and mitosis control biology. No guidance or outlook was provided.